Clene Inc. Current Liabilities
Clene Inc. (CLNN) had Current Liabilities of $4.85 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Liabilities, Current $4.85M.
- 2026-03-31: Liabilities, Current $6.73M.
- 2025-12-31: Liabilities, Current $10.78M.
- 2025-09-30: Liabilities, Current $8.31M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $4.85M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $6.73M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $10.78M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $8.31M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $7.57M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $10.76M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $10.29M 10-K · filed 2026-03-17 |
| 2024-09-30 | $23.83M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $28.07M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $26.18M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $25.33M 10-K · filed 2025-03-24 |
| 2023-09-30 | $15.27M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.74M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $16.88M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $13.86M 10-K · filed 2024-03-13 |
| 2022-09-30 | $6.15M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $7.66M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $5.47M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $6.03M 10-K · filed 2023-03-13 |
| 2021-09-30 | $4.83M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $4.52M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $4.09M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $11.67M 10-K · filed 2022-03-11 |
| 2019-12-31 | $4.31M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |